Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 122

    1.

    Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.

    Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX.

    J Hematol Oncol. 2009 Mar 16;2:13.

    PMID:
    19291303
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.

    Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem JL.

    Oncology. 2007;73(1-2):41-51. Epub 2008 Mar 11.

    PMID:
    18334830
    [PubMed - indexed for MEDLINE]
    3.

    Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.

    Brasiūnas V, Brasiūniene B, Juozaityte E, Barauskas G.

    Medicina (Kaunas). 2004;40(11):1074-80.

    PMID:
    15547308
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

    Ulrich-Pur H, Raderer M, Verena Kornek G, Schüll B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W.

    Br J Cancer. 2003 Apr 22;88(8):1180-4.

    PMID:
    12698181
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.

    Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG.

    Br J Cancer. 2003 Oct 20;89(8):1413-7.

    PMID:
    14562009
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

    Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pederzoli P, Falconi M.

    Anticancer Drugs. 2010 Apr;21(4):459-64.

    PMID:
    20110805
    [PubMed - indexed for MEDLINE]
    7.

    Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.

    Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA.

    Pancreas. 2008 Oct;37(3):269-74.

    PMID:
    18815548
    [PubMed - indexed for MEDLINE]
    8.

    Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.

    Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Yuzer Y, Goker E.

    Scand J Gastroenterol. 2005 Dec;40(12):1486-92.

    PMID:
    16293561
    [PubMed - indexed for MEDLINE]
    9.

    Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.

    Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC.

    Int J Gastrointest Cancer. 2002;32(1):35-41.

    PMID:
    12630768
    [PubMed - indexed for MEDLINE]
    10.

    Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.

    Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, Tanaka S, Nakaizumi A, Salem AA, Ueda R, Yamao K.

    J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1292-7.

    PMID:
    18700899
    [PubMed - indexed for MEDLINE]
    11.

    Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?

    Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T.

    Oncology. 2009;77(3-4):217-23. Epub 2009 Sep 4.

    PMID:
    19729980
    [PubMed - indexed for MEDLINE]
    12.

    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

    Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV.

    Ann Oncol. 2003 Jan;14(1):97-104.

    PMID:
    12488300
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.

    Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, Rowland KM Jr, Nair S, Tschetter LK, Fitch TR.

    J Clin Oncol. 2004 Dec 15;22(24):4944-50.

    PMID:
    15611509
    [PubMed - indexed for MEDLINE]
    14.

    Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

    Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ.

    Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46.

    PMID:
    10421536
    [PubMed - indexed for MEDLINE]
    15.

    Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.

    Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL.

    Clin Cancer Res. 2009 Apr 15;15(8):2913-9. Epub 2009 Mar 24.

    PMID:
    19318496
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

    Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

    Cancer Invest. 2003;21(4):489-96.

    PMID:
    14533437
    [PubMed - indexed for MEDLINE]
    17.

    Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

    Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP.

    J Clin Oncol. 2009 Nov 20;27(33):5513-8. Epub 2009 Oct 26.

    PMID:
    19858379
    [PubMed - indexed for MEDLINE]
    18.

    Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

    Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA.

    Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1293-302.

    PMID:
    11955742
    [PubMed - indexed for MEDLINE]
    19.

    Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.

    Neri B, Cipriani G, Grifoni R, Molinara E, Pantaleo P, Rangan S, Vannini A, Tonelli P, Valeri A, Pantalone D, Taddei A, Bechi P.

    Oncol Res. 2009;17(11-12):559-64.

    PMID:
    19806786
    [PubMed - indexed for MEDLINE]
    20.

    Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

    Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A.

    J Clin Oncol. 2002 Mar 15;20(6):1512-8.

    PMID:
    11896099
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk